ACOG: Protecting against HPV should begin early

Article

Vaccination against human papillomavirus should begin at age 11 and 12 years, according to ACOG committee opinion.

Vaccination against human papillomavirus (HPV) should begin at age 11 and 12 years, according to an American College of Obstetricians and Gynecologists committee opinion published in the September issue of Obstetrics and Gynecology. This opinion supports these same recommendations made by the federal Advisory Committee on Immunization Practices.

Girls as young as 9 years old can receive the vaccine, and those aged 13 through 26 years who have not received the vaccine should receive catch-up doses and complete the series of 3 vaccinations.

The vaccine is available in both bivalent and quadrivalent varieties. Both offer nearly 100% protection against precancerous changes in the cervix. The quadrivalent version also prevents lower genital tract condyloma. Patients should receive the vaccine before they become sexually active to gain maximum benefit; however, the vaccine can be given after a patient is sexually active.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Recent Videos
John Browning, MD, provides practical skincare reminders ahead of summer season
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Staphylococcus aureus risk in infants and neonatologist considerations with Aaron Milstone, MD
How fragrance plays a role in atopic dermatitis treatments, with John Browning, MD
Octavio Ramilo, MD, reacts to the FDA approval of clesrovimab for RSV prevention | Image Credit: St. Jude Children's Research Hospital
© 2025 MJH Life Sciences

All rights reserved.